Shopping Cart
- Remove All
- Your shopping cart is currently empty
CL-82198, a selective MMP-13 inhibitor, serves as a pharmacological intervention to halt the progression of osteoarthritis (OA). Its mechanism of action involves binding to the S1’ pocket of MMP-13, ensuring its selectivity and preventing inhibition of other MMPs.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | 37 € | In Stock | |
10 mg | 63 € | In Stock | |
25 mg | 147 € | In Stock | |
50 mg | 242 € | In Stock | |
100 mg | 377 € | In Stock | |
200 mg | 552 € | In Stock | |
500 mg | 867 € | In Stock | |
1 mL x 10 mM (in DMSO) | 40 € | In Stock |
Description | CL-82198, a selective MMP-13 inhibitor, serves as a pharmacological intervention to halt the progression of osteoarthritis (OA). Its mechanism of action involves binding to the S1’ pocket of MMP-13, ensuring its selectivity and preventing inhibition of other MMPs. |
In vitro | CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells[3]. CL-82198 (10 μM; 24 hours) obviously reduces LS174 cell migration[1]. |
In vivo | CL82198 (1-10 mg/kg; i.p.; every other day for 12 weeks) treatment avoids and decelerates MLI-induced osteoarthritis progression. |
Molecular Weight | 302.37 |
Formula | C17H22N2O3 |
Cas No. | 307002-71-7 |
Smiles | O=C(NCCCCN1CCOCC1)c1cc2ccccc2o1 |
Relative Density. | 1.159 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (330.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.